ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Tuesday, November 14, 2023

9:00AM-11:00AM
Abstract Number: 1727
Arthritogenicity of Homocitrullinated Peptides in HLA-DRB1 Transgenic Mice
(1713–1733) RA – Animal Models Poster
9:00AM-11:00AM
Abstract Number: 1919
Arthroplasty Outcomes in Immune Checkpoint Inhibitor-Treated Patients: A Single Center Series
(1913–1944) Miscellaneous Rheumatic & Inflammatory Diseases Poster III
9:00AM-11:00AM
Abstract Number: 1879
Artificial Intelligence for the Detection of Sacroiliitis on Magnetic Resonance Imaging in Patients with Axial Spondyloarthritis
(1862–1894) Imaging of Rheumatic Diseases Poster II
9:00AM-11:00AM
Abstract Number: 1903
Assessing Disparities Through Missing Race and Ethnicity Data: Results from a Juvenile Arthritis Registry
(1895–1912) Measures & Measurement of Healthcare Quality Poster II
9:00AM-11:00AM
Abstract Number: 1813
Assessing Immunogenicity of SARS-CoV-2 Vaccine Neoantigen S1 in Autoimmune Rheumatic Disease Patients: A Study on Cellular and Humoral Responses
(1796–1826) Epidemiology & Public Health Poster III
9:00AM-11:00AM
Abstract Number: 2315
Assessing Lupus Disease Activity Following the Onset of End-Stage Kidney Disease Within a Single Tertiary Centre in South London
(2257–2325) SLE – Diagnosis, Manifestations, & Outcomes Poster III
9:00AM-11:00AM
Abstract Number: 2037
Assessing Risk of Depression in Common Rheumatologic Disorders Using Diagnostic Codes, Survey Scores, and Propensity Score Matching Methodology
(2019–2038) Patient Outcomes, Preferences, & Attitudes Poster III
9:00AM-11:00AM
Abstract Number: 1870
Assessing the Appropriateness of Imaging Modalities in Primary Care for Low Back Pain and Their Impact on Outcomes: A Retrospective Observational Study in a Single Center in Trenton
(1862–1894) Imaging of Rheumatic Diseases Poster II
9:00AM-11:00AM
Abstract Number: 1900
Assessment of Hospitalist Confidence Levels in Management of Rheumatic Conditions to Identify Potential Knowledge Gaps
(1895–1912) Measures & Measurement of Healthcare Quality Poster II
9:00AM-11:00AM
Abstract Number: 2034
Assessment of the Immediate and Short-term Impact of an Information Course on Patients’ Knowledge About Rheumatoid Arthritis: Evaluation Using a Self-prepared and Validated Assessment Questionnaire
(2019–2038) Patient Outcomes, Preferences, & Attitudes Poster III
9:00AM-11:00AM
Abstract Number: 2296
Association Between EQ-5D-5L and SLEDAI Scores in Patients with Systemic Lupus Erythematosus in the United States and Europe: A Real-world Survey
(2257–2325) SLE – Diagnosis, Manifestations, & Outcomes Poster III
9:00AM-11:00AM
Abstract Number: 2187
Association Between Illness Perception, Anxiety and Depression State, Disease Activity and Glucocorticoid Therapy in Patients with Sjӧgren’s Syndrome
(2177–2194) Sjögren’s Syndrome – Basic & Clinical Science Poster II
9:00AM-11:00AM
Abstract Number: 1798
Association Between Knee Osteoarthritis and Mortality: A Serial Propensity Score-matched Cohort Study
(1796–1826) Epidemiology & Public Health Poster III
9:00AM-11:00AM
Abstract Number: 1992
Association Between Knee Osteoarthritis Pain and Concomitant Drug Use: A Post-hoc Analysis of Two Phase 3 Clinical Trials
(1977–1995) Osteoarthritis – Clinical Poster III
9:00AM-11:00AM
Abstract Number: 2096
Association of Left Ventricular Mass with Interleukin-17 in Rheumatoid Arthritis Patients Without Clinical Heart Failure
(2095–2140) RA – Diagnosis, Manifestations, and Outcomes Poster III
  • «Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 59
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology